News

Podcast

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Author(s):

Alexandra Gerlach, Associate Editor

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
API-CAT Findings Support Existing NCCN Cancer-Associated VTE Guidance
September 3rd 2025

API-CAT Findings Support Existing NCCN Cancer-Associated VTE Guidance

Belkis Kaplan, PharmD Resident
Pharmacy Focus Oncology Edition Podcast
September 3rd 2025

Protecting Community Oncology Practices in the Wake of the IRA

Alexandra Gerlach, Associate Editor
Box of depot medroxyprogesterone acetate | Image Credit: © Semi - stock.adobe.com
September 3rd 2025

Depot Medroxyprogesterone Acetate Linked to Higher Risk of Meningioma in Women

Alexandra Gerlach, Associate Editor
From Guidelines to Action: Pharmacy’s Role in Hypertension Management
September 3rd 2025

From Guidelines to Action: Pharmacy’s Role in Hypertension Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Model depicting chronic kidney disease (CKD) -- Image credit: NanSan | stock.adobe.com
September 3rd 2025

Regardless of Kidney Function, Abelacimab Consistently Reduced Bleeding Risk in Patients With AF

Gillian McGovern, Associate Editor
Clogged arteries, Cholesterol plaque in artery. 3d illustration - Image credit: Rasi | stock.adobe.com
September 3rd 2025

Enlicitide Offers a New Oral Option for Managing High Cholesterol

Kennedy Ferruggia, Assistant Editor
© 2025 MJH Life Sciences

All rights reserved.